Good evening and welcome to Markets Desk, your close-of-day read on what moved the needle.
Inflation watchers have fresh reason for concern tonight. Twenty-two V Research's Dennis DeBusschere is flagging a quiet but consequential shift: companies that were absorbing tariff costs through refund mechanisms are now running out of runway, and those higher input costs are increasingly heading straight to consumers. That changes the pricing calculus heading into year-end.
Turning to pharma, Eli Lilly is putting serious distance between itself and the GLP-one field. New head-to-head trial data shows its experimental drug retatrutide delivered roughly twice the weight loss of Ozempic. The compound is still working through clinical development and has no FDA approval yet, but this readout puts Lilly in a commanding position in what is already one of the most commercially significant drug categories in a generation.
And in a story that should matter to every CMO watching this broadcast, McDonald's is walking away from its thirty-two-year FIFA World Cup sponsorship. The move signals a broader reassessment among major global brands of whether mega-event deals still deliver the commercial return to justify their cost, particularly as media fragmentation makes mass-audience moments harder to monetize cleanly.
That's the tape. Markets Desk, signing off the floor.
